TruSight Oncology UMI Reagents

Error correction with unique molecular identifiers (UMIs) for next-generation sequencing libraries. Read More...
Select Product(s)

TruSight Oncology UMI Reagents (16 indexes, 48 samples)


Accessory Products
What accessories do I need?

TruSight® Tumor 170 Content Set



Product Highlights

These reagents reduce background noise in sequencing data, enabling detection of low-frequency variants, such as those found in cell-free DNA (cfDNA).

Reduced Error Rates

Circulating tumor DNA (ctDNA) may represent a very small fraction of cfDNA, near the limit of detection for next-generation sequencing (NGS). The TruSight Oncology UMI Reagents address this challenge with UMIs and error correction software, reducing error rates to < 0.007% and enabling detection of low-frequency variants. Lower error rates increase analytical specificity, resulting in higher confidence in NGS data.

Workflow Integration

The TruSight Oncology UMI Reagents include UMI adapters and indexes, plus DNA library prep and enrichment reagents. These reagents can also be paired with the TruSight Tumor 170 DNA oligos. Integration of UMIs does not create any extra steps in the library prep workflow.

Intuitive Software for Error Correction

The UMI Error Correction App aligns reads, then uses UMIs to exclude false positives, reducing variant calling errors. The UMI Error Correction App is available in the cloud-based BaseSpace Sequence Hub or for local installation.

See the Entire TruSight Oncology Product Family

Frequently Purchased Together


Method-Specific Workflow Example


Supporting Data and Figures

Background Reduction Facilitates Accurate Variant Calling
Background Reduction Facilitates Accurate Variant Calling

To enable accurate detection of rare variants, UMIs are integrated with error correction software, enabling true mutations to be distinguished from background noise. The bottom panel illustrates how, by removing inherent errors that result in false positives, the reduced error rate allows true mutations (red dots) to be better distinguished from background noise (grey dots).

Reduction of Error Rates with UMIs
Sequencing Run Mean Error Rate (Uncollapsed Reads) Mean Error Rate (Collapsed Reads)
1 0.038% 0.0023%
2 0.043% 0.0024%
3 0.035% 0.0024%
4 0.084% 0.0019%

Library preparation was performed using the TruSight Oncology UMI Reagents paired with DNA content from the TruSight Tumor 170 DNA assay, and 31 samples were distributed among four independent sequencing runs on the HiSeq 4000 System. Mean error rates are shown with and without collapsed reads using the UMI Error Correction App.

Related Products

TruSight Oncology 500

Assay targeting multiple variant types, including microsatellite instability (MSI) and tumor mutational burden (TMB).

TruSight Tumor 170

Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.

BaseSpace Sequence Hub

Data management and simplified bioinformatics for labs getting started and for rapidly scaling next-generation sequencing (NGS) operations.

* Performance on the NovaSeq 6000 System was demonstrated but not extensively tested.